Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsPreferred Shares RepurchasedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Share-based Compensation (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Share-based Compensation for 15 consecutive years, with $60492.0 as the latest value for Q1 2026.

  • Quarterly Share-based Compensation fell 16.97% to $60492.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $660113.0 through Jan 2026, up 59.18% year-over-year, with the annual reading at $478637.0 for FY2025, 29.06% down from the prior year.
  • Share-based Compensation for Q1 2026 was $60492.0 at PharmaCyte Biotech, roughly flat from $60492.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $674693.0 in Q1 2024, with the low at $2278.0 in Q3 2022.
  • Average Share-based Compensation over 4 years is $175484.8, with a median of $66675.5 recorded in 2025.
  • The sharpest move saw Share-based Compensation plummeted 89.2% in 2025, then decreased 16.97% in 2026.
  • Over 4 years, Share-based Compensation stood at $2278.0 in 2022, then surged by 5130.68% to $119155.0 in 2024, then tumbled by 49.23% to $60492.0 in 2025, then changed by 0.0% to $60492.0 in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $60492.0, $60492.0, and $60492.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.